
Quantum-Si Incorporated (NASDAQ:QSI – Free Report) – Research analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for shares of Quantum-Si in a research note issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.12). The consensus estimate for Quantum-Si’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Quantum-Si’s Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.48) EPS and FY2028 earnings at ($0.37) EPS.
Quantum-Si (NASDAQ:QSI – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%.The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.30 million.
Quantum-Si Trading Up 2.4%
NASDAQ QSI opened at $0.94 on Wednesday. Quantum-Si has a 1 year low of $0.69 and a 1 year high of $3.10. The company has a fifty day simple moving average of $0.89 and a 200 day simple moving average of $1.17. The company has a market cap of $204.36 million, a P/E ratio of -1.85 and a beta of 3.15.
Insider Activity at Quantum-Si
In other Quantum-Si news, CEO Jeffrey Alan Hawkins sold 83,712 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $1.01, for a total value of $84,549.12. Following the completion of the transaction, the chief executive officer owned 3,776,135 shares of the company’s stock, valued at $3,813,896.35. This represents a 2.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Paula Dowdy acquired 109,890 shares of Quantum-Si stock in a transaction on Thursday, March 5th. The stock was purchased at an average price of $0.95 per share, with a total value of $104,395.50. Following the transaction, the director directly owned 269,107 shares in the company, valued at approximately $255,651.65. This trade represents a 69.02% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 212,904 shares of company stock worth $205,021 in the last three months. Corporate insiders own 22.04% of the company’s stock.
Institutional Investors Weigh In On Quantum-Si
Institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC acquired a new position in shares of Quantum-Si in the 1st quarter valued at $4,721,000. State Street Corp raised its position in Quantum-Si by 26.5% in the fourth quarter. State Street Corp now owns 3,562,721 shares of the company’s stock worth $3,919,000 after purchasing an additional 745,231 shares in the last quarter. Squarepoint Ops LLC bought a new position in Quantum-Si during the third quarter worth about $865,000. Bank of America Corp DE boosted its holdings in Quantum-Si by 426.6% during the second quarter. Bank of America Corp DE now owns 465,999 shares of the company’s stock valued at $913,000 after purchasing an additional 377,504 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Quantum-Si by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 4,114,375 shares of the company’s stock valued at $4,527,000 after purchasing an additional 367,206 shares during the period. Institutional investors own 39.90% of the company’s stock.
About Quantum-Si
Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.
Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.
See Also
- Five stocks we like better than Quantum-Si
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
Receive News & Ratings for Quantum-Si Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum-Si and related companies with MarketBeat.com's FREE daily email newsletter.
